Related Experiment Video
Updated: Feb 5, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Bergapten inhibits liver carcinogenesis by modulating LXR/PI3K/Akt and IDOL/LDLR pathways
Shakti Prasad Pattanayak1, Pritha Bose1, Priyashree Sunita2
1Division of Advanced Pharmacology, Department of Pharm. Sciences & Technology, Birla Institute of Technology, Mesra, Ranchi, 835215, India.
Abstract:
Oxysterol receptors LXRs (α and β) are recently reported to be one of the novel and potential therapeutic targets in reducing cell proliferation and tumor growth in different system model. Activation of LXRs is correlated with modification of PI3K/Akt pathway. LXRs are also found to play a critical role in maintaining lipid homeostatais by regulating ABCA1, IDOL, SREBP1, LDLR and also certain lipogenic genes such as FASN and SCD1. In the present study a potential furanocoumarin, Bergapten (BeG) has been evaluated for its anticancer property on Hepatocellular Carcinoma (HCC) on LXR axis. The molecular docking analysis was carried out for BeG on LXR (α & β) using Maestro tool and compared with reference ligands. This was followed by in vitro (HepG2 cell lines) and in vivo (on NDEA induced HCC in Wistar albino rats) anticancer evaluation of BeG. The docking results revealed polar and hydrophobic interactions of BeG with LXR (α,β). The in vitro studies revealed the potential of BeG in lowering the accumulation of lipid droplets in HepG2 cells which was correlated with increase in LXR (α,β) protein expressions. Furthermore, the in vivo studies demonstrated the potential of BeG in ameliorating the cancer induced alterations in body weight, liver weight and significant restoration of the changes in mRNA and protein expressions of LXR(α,β), ABCA1, IDOL, SREBP1 and LDLR. BeG also modulated the expressions of PI3K, Akt and certain lipogenic genes like FASN and SCD1 and reduced the lipid droplets level in liver cancer cells. These results provide evidence and validates the critical role of BeG in maintaining the lipid homeostasis and justifies its anticancer potential against NDEA-induced HCC.
Insights
Bergapten (BeG) shows anticancer potential against liver cancer by targeting liver X receptors (LXRs). This furanocoumarin helps restore lipid homeostasis and reduces tumor growth in preclinical models.
Area of Science:
- Biochemistry
- Pharmacology
- Oncology
Background:
- Liver X receptors (LXRs) are emerging therapeutic targets for cancer, influencing cell proliferation and lipid metabolism.
- LXR activation impacts pathways like PI3K/Akt and regulates genes involved in lipid homeostasis (ABCA1, IDOL, SREBP1, LDLR, FASN, SCD1).
Purpose of the Study:
- To evaluate the anticancer properties of Bergapten (BeG), a furanocoumarin, against Hepatocellular Carcinoma (HCC) by targeting the LXR axis.
- To investigate BeG's effects on lipid metabolism and key molecular pathways in HCC models.
Main Methods:
- Molecular docking of BeG on LXR (α,β) using Maestro.
- In vitro anticancer evaluation using HepG2 cell lines.
- In vivo anticancer evaluation in NDEA-induced HCC in Wistar albino rats.
Main Results:
- BeG demonstrated polar and hydrophobic interactions with LXR (α,β) in docking studies.
- In vitro, BeG reduced lipid droplet accumulation in HepG2 cells, correlating with increased LXR (α,β) expression.
- In vivo, BeG ameliorated cancer-induced alterations in body and liver weight, restored gene/protein expression of LXR pathway components, and modulated PI3K/Akt and lipogenic genes.
Conclusions:
- BeG exhibits significant anticancer potential against NDEA-induced HCC.
- BeG's mechanism involves restoring lipid homeostasis and modulating key cancer-related pathways via the LXR axis.
- These findings validate BeG as a promising therapeutic agent for HCC.
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
Feedback Inhibition
C4 Pathway and CAM
C4 Pathway
The C4 pathway is used by plants such as...
Enzyme Inhibition
Inhibition of Cdk Activity
Other Glycolytic Pathways

